These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12056292)

  • 21. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.
    Clegg DO; Reda DJ; Abdellatif M
    Arthritis Rheum; 1999 Nov; 42(11):2325-9. PubMed ID: 10555027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
    Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
    J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials.
    Chen J; Liu C
    J Rheumatol; 2006 Apr; 33(4):722-31. PubMed ID: 16583475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Basic therapeutics in the management of various forms of arthritis].
    Sieper J
    Orthopade; 1998 Aug; 27(8):576-80. PubMed ID: 9779434
    [No Abstract]   [Full Text] [Related]  

  • 25. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients.
    Dougados M; Boumier P; Amor B
    Br Med J (Clin Res Ed); 1986 Oct; 293(6552):911-4. PubMed ID: 2876744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical appraisal of the guidelines for the management of ankylosing spondylitis: disease-modifying antirheumatic drugs.
    Soriano ER; Clegg DO; Lisse JR
    Am J Med Sci; 2012 May; 343(5):357-9. PubMed ID: 22543537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conventional DMARDs in axial spondyloarthritis: wishful--rather than rational--thinking!
    Landewé RB
    Ann Rheum Dis; 2015 Jun; 74(6):951-3. PubMed ID: 25795908
    [No Abstract]   [Full Text] [Related]  

  • 28. Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.
    van der Horst-Bruinsma IE; Zack DJ; Szumski A; Koenig AS
    Ann Rheum Dis; 2013 Jul; 72(7):1221-4. PubMed ID: 23264358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are there any antirheumatic drugs that modify the course of ankylosing spondylitis?
    Laurent R
    Baillieres Clin Rheumatol; 1990 Aug; 4(2):387-400. PubMed ID: 1674450
    [No Abstract]   [Full Text] [Related]  

  • 30. Meta-analysis of sulfasalazine in ankylosing spondylitis.
    Ferraz MB; Tugwell P; Goldsmith CH; Atra E
    J Rheumatol; 1990 Nov; 17(11):1482-6. PubMed ID: 1980310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulphasalazine and ankylosing spondylitis.
    McConkey B
    Br J Rheumatol; 1990 Feb; 29(1):2-3. PubMed ID: 1968352
    [No Abstract]   [Full Text] [Related]  

  • 32. Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: a real-life experience.
    Can M; Aydın SZ; Niğdelioğlu A; Atagündüz P; Direskeneli H
    Int J Rheum Dis; 2012 Dec; 15(6):526-30. PubMed ID: 23253235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraarticular injection of infliximab.
    Sakellariou GT; Kakavouli G; Chatzigiannis I
    J Rheumatol; 2006 Sep; 33(9):1912-3; author reply 1913. PubMed ID: 16960955
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
    Goodemote P; Jamieson B; Hoffman R
    J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
    [No Abstract]   [Full Text] [Related]  

  • 35. Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study.
    Tam HW; Yeo KJ; Leong PY; Chen CH; Li YC; Ma CM; Wang YH; Chiou JY; Wei JC
    Int J Rheum Dis; 2017 Mar; 20(3):363-370. PubMed ID: 27943609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic aspects of spondyloarthropathies -- a review.
    Leirisalo-Repo M
    Scand J Rheumatol; 1998; 27(5):323-8. PubMed ID: 9808393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Andersson lesion in ankylosing spondylitis.
    Dhakad U; Das SK
    BMJ Case Rep; 2013 Apr; 2013():. PubMed ID: 23559648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication toxicity among patients with ankylosing spondylitis.
    Ward MM; Kuzis S
    Arthritis Rheum; 2002 Jun; 47(3):234-41. PubMed ID: 12115151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma homocysteine status in patients with ankylosing spondylitis.
    Wei JC; Jan MS; Yu CT; Huang YC; Yang CC; Tsou HK; Lee HS; Chou CT; Tsay G; Chou MC
    Clin Rheumatol; 2007 May; 26(5):739-42. PubMed ID: 17024318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.
    Machado P; Landewé R; Lie E; Kvien TK; Braun J; Baker D; van der Heijde D;
    Ann Rheum Dis; 2011 Jan; 70(1):47-53. PubMed ID: 21068095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.